Ilacirnon

DB16066InvestigationalSmall molecule

Ilacirnon (CCX-140) is under investigation in clinical trial NCT01440257 (A Study to Evaluate the Effect of CCX140-B on Urinary Albumin Excretion in Subjects With Type 2 Diabetes and Albuminuria).

Mechanism: Pharmacologically active on C-C chemokine receptor type 2
Curator reviewed
Formula / weight: C₂₀H₁₃ClF₃N₅O₃S · 495.86 g/mol (avg)
Code names: CCX-140

Resolves to

Compound

UNII380F68J5PHCAS1100318-47-5ChEMBLCHEMBL2178573

Structure

InChIKeyLUUMLYXKTPBTQR-UHFFFAOYSA-NSMILESCC1=CC(NS(=O)(=O)C2=CC=C(Cl)C(=C2)C(F)(F)F)=C(N=C1)C(=O)C1=C2C=CNC2=NC=N1

Targets

P41597CCR2

What you can answer from here — as of July 17, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Ilacirnon, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account